Welcome to our dedicated page for Airsculpt Technologies news (Ticker: AIRS), a resource for investors and traders seeking the latest updates and insights on Airsculpt Technologies stock.
AirSculpt Technologies, Inc. provides premium body contouring procedures through AirSculpt offices. Its AirSculpt method is a minimally invasive treatment for fat removal, skin tightening, targeted body sculpting, and fat transfer procedures that use a patient’s own fat cells.
Company news centers on operating results, same-center and same-store sales trends, case volume, revenue, adjusted EBITDA, guidance, marketing initiatives, new procedure categories, balance sheet activity, and governance changes. Updates also address the company’s positioning within aesthetics demand tied to GLP-1 use and its direct medical procedure services model.
AirSculpt Technologies (NASDAQ:AIRS) reported fiscal Q2 2026 revenue of $42.9 million, down 3% year over year, on case volume of 3,376, down 0.5%. Net loss widened to $1.1 million from $0.6 million, while Adjusted EBITDA declined to $4.9 million from $5.8 million, with an 11.5% margin.
Same-center cases grew 1.0% in Q2 and 1.1% year-to-date, with essentially flat same-center sales. Year-to-date revenue fell 1.3% to $82.3 million and net loss was $3.5 million. According to the company, an exclusive partnership with AlloClae is expected to broaden its injectable adipose matrix offering.
Since early 2025, gross debt fell by about $30 million to $44.2 million and cash increased by roughly $10 million to $18.8 million. AirSculpt reaffirmed full-year 2026 revenue at the lower end of its $151–$157 million range and reduced Adjusted EBITDA guidance to $12–$14 million. A term loan amendment extends maturity to November 2027 and adds prepayment requirements tied to future equity issuance.
AirSculpt Technologies (NASDAQ: AIRS) will release its second quarter fiscal 2026 financial results before the market opens on Monday, August 10, 2026, followed by a conference call at 8:30 a.m. Eastern Time, accessible via telephone and live webcast on its investor relations website.
The company will also participate in Canaccord Genuity's 46th Annual Growth Conference at the InterContinental Boston Hotel on August 11, 2026, with a management presentation at 4:30 p.m. Eastern Time, which will be webcast live for investors.
AirSculpt Technologies (NASDAQ:AIRS) will participate in two June 2026 investor conferences. Management will present and hold investor meetings at both events, with fireside chats webcast live and available for replay on the company’s investor relations website.
The conferences are hosted by TD Cowen and Oppenheimer.
AirSculpt Technologies (NASDAQ:AIRS) reported first quarter fiscal 2026 results for the period ended March 31, 2026. Key metrics: revenue $39.4M (flat), case volume 3,082 (+0.2% vs FY25 Q1), same center sales +1%, net loss $2.4M, and adjusted EBITDA $3.3M. The company reaffirmed full‑year 2026 guidance of $151–$157M revenue and $15–$17M adjusted EBITDA. Liquidity included $16.7M cash, ~$45.6M gross debt, $5.0M revolver capacity, and $14.6M raised via ATM with $11.4M debt paydown in Q1.
AirSculpt Technologies (NASDAQ: AIRS) will report Q1 2026 results before market open on May 8, 2026, followed by a conference call at 8:30 a.m. ET. The call includes domestic and international dial-in numbers and a live webcast via the company investor relations site.
The webcast replay will be available for about 90 days. Management will present at the Wolfe Research Global Consumer Growth Conference (virtual) on May 18, 2026 and at the LD Micro Invitational (Los Angeles) on May 19, 2026; both presentations will be viewable on the investor relations page.
AirSculpt Technologies (NASDAQ:AIRS) reported corrected fourth-quarter and full-year 2025 results, updating Adjusted EBITDA and related metrics due to a one-time non-cash London facility adjustment. FY2025 revenue fell to $151.8M, Adjusted EBITDA was $12.5M, and net loss was $11.7M. The company provided 2026 guidance and noted improved same-store sales in early 2026.
Liquidity included $8.4M cash at Dec 31, 2025, $5.0M revolver capacity, and gross debt reduced to ~$45.0M after an ATM raise and debt paydown in Q1 2026.
AirSculpt Technologies (NASDAQ:AIRS) reported fourth-quarter and full-year fiscal 2025 results, with revenue of $33.4M in Q4 and $151.8M for full-year 2025. Case volume declined ~15% year-over-year to 2,604 in Q4 and 11,852 for 2025. Full-year adjusted EBITDA was $15.1M and net loss was $11.7M. The company issued 2026 guidance of $151–$157M revenue and $15–$17M adjusted EBITDA. As of Dec 31, 2025 cash was $8.4M, gross debt ~$56M, with subsequent ATM proceeds of $14.8M and debt reduced to ~$45M.
AirSculpt set its annual meeting for May 12, 2026 and will host a conference call on April 2, 2026.
AirSculpt Technologies (NASDAQ: AIRS) will report fourth quarter and fiscal year 2025 results before market open on Thursday, April 2, 2026, followed by a conference call at 8:30 a.m. Eastern Time the same day.
Investors may join by domestic toll-free dial-in, international dial-in with conference ID 13758597, or via the live webcast in the investor relations section. A replay will be available for approximately 90 days.
AirSculpt (NASDAQ:AIRS) expects to file a Form 12b-25 on March 16, 2026, to delay its Form 10-K filing for the year ended December 31, 2025, by 15 days while it completes classification of inter-company transactions and balances.
Preliminary fiscal 2025 revenue was $151.8 million, Q4 2025 preliminary revenue was $33.4 million, Q1 2026 revenue is estimated at $38.5–$39.5 million, cash was $13.0 million and debt $46.0 million. Same-store sales improved in February 2026.
AirSculpt Technologies (NASDAQ:AIRS) announced on November 17, 2025 that Mike Doyle has been appointed Non-Executive Chairman of the company's board.
Mr. Doyle brings over 30 years of multi-center healthcare leadership and recent private-equity and operating experience, including roles as Managing Partner of Vesey Street Capital Partners since January 2025, founder and CEO of MD Healthcare Partners (2018–Dec 2024), and CEO of Surgery Partners (2009–Sept 2017) where he helped scale the business from 3 to over 175 locations.
The appointment highlights board-level reinforcement as AirSculpt pursues its next phase of transformation and leverages Doyle's experience with multi-site operations and surgeon partnerships.